Concomitant deficiency of β- and γ-sarcoglycans in 20 α-sarcoglycan (adhalin)-deficient patients: Immunohistochemical analysis and clinical aspects

Rita Barresi, Valeria Confalonieri, Massimo Lanfossi, Claudia Di Blasi, Elena Torchiana, Renato Mantegazza, Laura Jarre, Nardo Nardocci, Patrizia Boffi, Frediano Tezzon, Antonella Pini, Ferdinando Cornelio, Marina Mora, Lucia Morandi

Research output: Contribution to journalArticle

Abstract

We have investigated the expression, using immunohistochemistry, of β- and γ-sarcoglycans in the muscles of 20 patients in whom previous screening had revealed a deficiency of α-sarcoglycan. α-, β- and γ-sarcoglycans were absent in 7 patients and variably reduced in 8 patients, in 2 of whom β-sarcoglycan was more reduced than the α- and γ-proteins. In 5 other patients with variably reduced α- and β-sarcoglycans, γ-sarcoglycan was completely absent. In all patients the distribution of hyposthenia at disease onset was similar, and predominantly involved pelvic girdle muscles; however, the age at onset and rate of disease progression were highly variable. In severely compromised patients, the onset of disease was before 10 years of age and γ-sarcoglycan or all three sarcoglycans were absent from muscles. Immunohistochemical analysis of sarcoglycans should be part of routine screening for muscle dystrophies to identify patients with sarcoglycanopathy. Gene analysis is necessary to identify the primary defect; however, sarcoglycan immunohistochemistry may be useful for indicating which gene to investigate. Further biochemical characterization of the interactions between these proteins is required to fully elucidate their roles in causing severe, moderate or mild muscular dystrophy.

Original languageEnglish
Pages (from-to)28-35
Number of pages8
JournalActa Neuropathologica
Volume94
Issue number1
DOIs
Publication statusPublished - Jul 1997

Fingerprint

Sarcoglycans
Muscles
Sarcoglycanopathies
Immunohistochemistry
Muscular Dystrophies
Age of Onset
Genes
Disease Progression
Proteins

Keywords

  • Dystrophin-associated proteins
  • Dystrophin-glycoprotein complex
  • Limb-girdle muscular dystrophy
  • Sarcoglycans
  • Severe childhood autosomal recessive muscular dystrophy

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Concomitant deficiency of β- and γ-sarcoglycans in 20 α-sarcoglycan (adhalin)-deficient patients : Immunohistochemical analysis and clinical aspects. / Barresi, Rita; Confalonieri, Valeria; Lanfossi, Massimo; Di Blasi, Claudia; Torchiana, Elena; Mantegazza, Renato; Jarre, Laura; Nardocci, Nardo; Boffi, Patrizia; Tezzon, Frediano; Pini, Antonella; Cornelio, Ferdinando; Mora, Marina; Morandi, Lucia.

In: Acta Neuropathologica, Vol. 94, No. 1, 07.1997, p. 28-35.

Research output: Contribution to journalArticle

Barresi, Rita ; Confalonieri, Valeria ; Lanfossi, Massimo ; Di Blasi, Claudia ; Torchiana, Elena ; Mantegazza, Renato ; Jarre, Laura ; Nardocci, Nardo ; Boffi, Patrizia ; Tezzon, Frediano ; Pini, Antonella ; Cornelio, Ferdinando ; Mora, Marina ; Morandi, Lucia. / Concomitant deficiency of β- and γ-sarcoglycans in 20 α-sarcoglycan (adhalin)-deficient patients : Immunohistochemical analysis and clinical aspects. In: Acta Neuropathologica. 1997 ; Vol. 94, No. 1. pp. 28-35.
@article{afb09c5faed84d02a4b552a26fdcb8b6,
title = "Concomitant deficiency of β- and γ-sarcoglycans in 20 α-sarcoglycan (adhalin)-deficient patients: Immunohistochemical analysis and clinical aspects",
abstract = "We have investigated the expression, using immunohistochemistry, of β- and γ-sarcoglycans in the muscles of 20 patients in whom previous screening had revealed a deficiency of α-sarcoglycan. α-, β- and γ-sarcoglycans were absent in 7 patients and variably reduced in 8 patients, in 2 of whom β-sarcoglycan was more reduced than the α- and γ-proteins. In 5 other patients with variably reduced α- and β-sarcoglycans, γ-sarcoglycan was completely absent. In all patients the distribution of hyposthenia at disease onset was similar, and predominantly involved pelvic girdle muscles; however, the age at onset and rate of disease progression were highly variable. In severely compromised patients, the onset of disease was before 10 years of age and γ-sarcoglycan or all three sarcoglycans were absent from muscles. Immunohistochemical analysis of sarcoglycans should be part of routine screening for muscle dystrophies to identify patients with sarcoglycanopathy. Gene analysis is necessary to identify the primary defect; however, sarcoglycan immunohistochemistry may be useful for indicating which gene to investigate. Further biochemical characterization of the interactions between these proteins is required to fully elucidate their roles in causing severe, moderate or mild muscular dystrophy.",
keywords = "Dystrophin-associated proteins, Dystrophin-glycoprotein complex, Limb-girdle muscular dystrophy, Sarcoglycans, Severe childhood autosomal recessive muscular dystrophy",
author = "Rita Barresi and Valeria Confalonieri and Massimo Lanfossi and {Di Blasi}, Claudia and Elena Torchiana and Renato Mantegazza and Laura Jarre and Nardo Nardocci and Patrizia Boffi and Frediano Tezzon and Antonella Pini and Ferdinando Cornelio and Marina Mora and Lucia Morandi",
year = "1997",
month = "7",
doi = "10.1007/s004010050668",
language = "English",
volume = "94",
pages = "28--35",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Concomitant deficiency of β- and γ-sarcoglycans in 20 α-sarcoglycan (adhalin)-deficient patients

T2 - Immunohistochemical analysis and clinical aspects

AU - Barresi, Rita

AU - Confalonieri, Valeria

AU - Lanfossi, Massimo

AU - Di Blasi, Claudia

AU - Torchiana, Elena

AU - Mantegazza, Renato

AU - Jarre, Laura

AU - Nardocci, Nardo

AU - Boffi, Patrizia

AU - Tezzon, Frediano

AU - Pini, Antonella

AU - Cornelio, Ferdinando

AU - Mora, Marina

AU - Morandi, Lucia

PY - 1997/7

Y1 - 1997/7

N2 - We have investigated the expression, using immunohistochemistry, of β- and γ-sarcoglycans in the muscles of 20 patients in whom previous screening had revealed a deficiency of α-sarcoglycan. α-, β- and γ-sarcoglycans were absent in 7 patients and variably reduced in 8 patients, in 2 of whom β-sarcoglycan was more reduced than the α- and γ-proteins. In 5 other patients with variably reduced α- and β-sarcoglycans, γ-sarcoglycan was completely absent. In all patients the distribution of hyposthenia at disease onset was similar, and predominantly involved pelvic girdle muscles; however, the age at onset and rate of disease progression were highly variable. In severely compromised patients, the onset of disease was before 10 years of age and γ-sarcoglycan or all three sarcoglycans were absent from muscles. Immunohistochemical analysis of sarcoglycans should be part of routine screening for muscle dystrophies to identify patients with sarcoglycanopathy. Gene analysis is necessary to identify the primary defect; however, sarcoglycan immunohistochemistry may be useful for indicating which gene to investigate. Further biochemical characterization of the interactions between these proteins is required to fully elucidate their roles in causing severe, moderate or mild muscular dystrophy.

AB - We have investigated the expression, using immunohistochemistry, of β- and γ-sarcoglycans in the muscles of 20 patients in whom previous screening had revealed a deficiency of α-sarcoglycan. α-, β- and γ-sarcoglycans were absent in 7 patients and variably reduced in 8 patients, in 2 of whom β-sarcoglycan was more reduced than the α- and γ-proteins. In 5 other patients with variably reduced α- and β-sarcoglycans, γ-sarcoglycan was completely absent. In all patients the distribution of hyposthenia at disease onset was similar, and predominantly involved pelvic girdle muscles; however, the age at onset and rate of disease progression were highly variable. In severely compromised patients, the onset of disease was before 10 years of age and γ-sarcoglycan or all three sarcoglycans were absent from muscles. Immunohistochemical analysis of sarcoglycans should be part of routine screening for muscle dystrophies to identify patients with sarcoglycanopathy. Gene analysis is necessary to identify the primary defect; however, sarcoglycan immunohistochemistry may be useful for indicating which gene to investigate. Further biochemical characterization of the interactions between these proteins is required to fully elucidate their roles in causing severe, moderate or mild muscular dystrophy.

KW - Dystrophin-associated proteins

KW - Dystrophin-glycoprotein complex

KW - Limb-girdle muscular dystrophy

KW - Sarcoglycans

KW - Severe childhood autosomal recessive muscular dystrophy

UR - http://www.scopus.com/inward/record.url?scp=0030792467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030792467&partnerID=8YFLogxK

U2 - 10.1007/s004010050668

DO - 10.1007/s004010050668

M3 - Article

C2 - 9224527

AN - SCOPUS:0030792467

VL - 94

SP - 28

EP - 35

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 1

ER -